

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent:	H9 Cells
Catalog Number:	87
Lot Number:	130029
Release Category:	C
Provided:	5×10^6 cells/mL. Viability is 92%.
Cell Type:	Single cell clone derived from a specific HUT 78 cell line, HT. HUT 78 is a human cutaneous T cell lymphoma derived from the peripheral blood of a patient with Sezary syndrome.
Propagation Medium:	RPMI 1640, supplemented with 2 mM L-glutamine and 50 $\mu g/ml$ gentamicin, 90%; fetal bovine serum, 10%.
Freeze Medium:	RPMI 1640, 80%; fetal bovine serum, 10%; DMSO, 10%.
Growth Characteristics:	Maintain H9 cells at 1 x 10^5 - 1 x 10^6 cells/ml. Split 1:2-1:4 twice weekly. H9 grows as a single cell suspension with some clumping. Morphology is mature lymphocytic.
Special Characteristics:	This cell line was selected for high yield permissive growth with HIV-1.
Recommended Storage:	Liquid nitrogen.
Contributor:	Dr. Robert Gallo

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

References:	Mann DL, O'Brien SJ, Gilbert DA, Reid Y, Popovic M, Read-Connole E, Gallo R, Gazdar A. Origin of the HIV-susceptible human CD4 + cell line H9. <i>AIDS Res Hum Retroviruses</i> 5 :253-255, 1989.
	Popovic M, Read-Connole E, Gallo RC. T4 positive human neoplastic cell lines susceptible to and permissive for HTLV-III. <i>Lancet</i> ii:1472-1473, 1984.
	Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. <i>Science</i> 224 :497-500, 1984.
NOTE:	Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: H9 from Dr. Robert Gallo." Also include the references cited above in any publications.
	The use of the H9 cell line and other neoplastic T cell lines to produce HIV-1 is described in U.S. Patent 4,520,113.
Last Updated	November 02, 2015

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.